STIM Neuronetics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1227636 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.0%
TTM net income YoY48.1%
TTM EPS YoY61.4%
Revenue 3-yr CAGR32.1%
Net income 3-yr CAGR—
Margins
Gross margin50.7%
Operating margin-9.4%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-8.0%
Returns
ROE-100.2%
ROA-16.6%
ROIC (approx.)-19.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets83.0%
Debt / equity3.30x
Current ratio2.01x
Interest coverage-1.69x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-10.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $41.96M | $41.57M | $34.45M | $41.78M | $37.30M | $38.11M | $31.98M | $22.49M |
| Cost of revenue | $20.07M | $20.34M | $18.30M | $20.07M | $20.19M | $20.35M | $16.24M | $7.60M |
| Gross profit | $21.89M | $21.22M | $16.15M | $21.70M | $17.11M | $17.76M | $15.74M | $14.89M |
| R&D expense | $1.19M | $1.34M | $1.36M | $1.67M | $1.50M | $1.80M | $1.62M | $5.77M |
| SG&A expense | $11.68M | $11.40M | $13.05M | $13.34M | $11.08M | $12.15M | $13.14M | $10.78M |
| Operating income | $541,000 | -$1.50M | -$8.99M | -$5.04M | -$7.32M | -$8.06M | -$11.01M | -$11.47M |
| Interest expense | $2.14M | $2.12M | $2.27M | $2.32M | $2.21M | $1.97M | $1.92M | $1.76M |
| Net income | -$1.69M | -$3.44M | -$10.79M | -$7.16M | -$9.04M | -$10.12M | -$12.68M | -$12.66M |
| EBITDA | $841,000 | -$1.10M | -$8.25M | -$4.28M | -$6.82M | -$7.56M | -$10.10M | -$11.03M |
| EPS (basic) | -0.02 | -0.05 | -0.16 | — | -0.13 | -0.15 | -0.21 | — |
| EPS (diluted) | -0.02 | -0.05 | -0.16 | — | -0.13 | -0.15 | -0.21 | — |
| Weighted avg. shares (diluted) | 77.00M | 73.13M | 69.59M | — | 67.31M | 66.18M | 61.47M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.11M | $19.20M | $13.21M | $28.13M | $27.97M | $10.97M | $20.22M | $19.46M |
| Receivables | $14.44M | $15.96M | $15.81M | $16.47M | $18.69M | $26.12M | $26.20M | $23.36M |
| Inventory | $4.94M | $5.50M | $4.71M | $4.33M | $4.32M | $4.94M | $4.07M | $4.25M |
| Current assets | $53.89M | $53.23M | $47.17M | $61.55M | $64.89M | $56.14M | $60.67M | $58.12M |
| PP&E, net | $3.18M | $3.46M | $3.87M | $4.47M | $4.94M | $5.32M | $5.85M | $6.24M |
| Goodwill | $23.62M | $23.62M | $23.62M | $23.62M | $22.66M | $19.08M | $18.63M | $18.63M |
| Intangibles | $17.06M | $17.42M | $17.79M | $18.15M | $18.51M | $18.88M | $19.24M | $19.61M |
| Total assets | $131.96M | $131.53M | $125.44M | $141.55M | $145.47M | $134.65M | $141.99M | $140.90M |
| Current liabilities | $26.86M | $28.31M | $28.29M | $30.52M | $28.94M | $27.80M | $24.84M | $31.27M |
| Long-term debt | $61.75M | $61.52M | $61.30M | $65.81M | $65.67M | $55.54M | $55.34M | $55.15M |
| Total debt | $61.75M | $61.52M | $61.30M | $65.81M | $65.67M | $55.54M | $55.34M | $55.15M |
| Total liabilities | $109.56M | $109.89M | $108.38M | $115.31M | $114.11M | $103.14M | $102.46M | $109.10M |
| Shareholders' equity | $18.71M | $17.85M | $13.27M | $22.38M | $27.36M | $27.15M | $35.45M | $27.71M |
| Net debt | $39.65M | $42.32M | $48.08M | $37.67M | $37.70M | $44.57M | $35.12M | $35.69M |
| Shares outstanding | 77.73M | 76.19M | 69.58M | 68.99M | 68.44M | 66.11M | 65.82M | 55.68M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.24M | -$1.01M | -$9.42M | $908,000 | -$785,000 | -$3.50M | -$16.99M | -$8.60M |
| Capital expenditure | $470,000 | $417,000 | $197,000 | $216,000 | $114,000 | $252,000 | $219,000 | $89,000 |
| Free cash flow | $768,000 | -$1.43M | -$9.62M | $692,000 | -$899,000 | -$3.76M | -$17.21M | -$8.69M |
| Investing cash flow | -$470,000 | -$417,000 | -$172,000 | -$216,000 | -$114,000 | -$252,000 | -$219,000 | -$2.38M |
| Financing cash flow | $2.14M | $7.41M | -$5.58M | -$1.03M | $17.90M | $1,000 | $18.98M | $9.56M |
| Depreciation & amortization | $300,000 | $400,000 | $745,000 | $767,000 | $500,000 | $500,000 | $911,000 | $446,000 |
| Stock-based compensation | $178,000 | $688,000 | $1.68M | $2.18M | $1.41M | $1.81M | $1.44M | $1.28M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.